Tagged Articles

Actos 310 articles

Diabetes drug Actos linked to weight gain

Obesity is a risk factor for type 2 diabetes and most patients who suffer from the condition are encouraged to lose weight. However, a type of commonly used diabetes drugs can actually increase body fat in people, according to new research published in The Journal of Neuroscience. The body fat increase was associated with a class of type 2 diabetes drugs known as thiazolidinediones, or TZDs. Drugs in this class include Actos (pioglitazone), Actoplus Met (pioglitazone and metformin), Duetact (pioglitazone and glimepride), Avandia (rosiglitazone), Avandamet (rosiglitazone and metformin), and Avandaryl (rosiglitazone and glimepride). The medical community has known for a ... Read More

Cough medicine may help lower blood sugar in diabetic patients

An ingredient found in over-the-counter cough medicines may help lower blood sugar levels and could one day be used for the treatment of type 2 diabetes, according to new research published in the journal Nature Medicine. Researchers at Heinrich Heine University in Dusseldorf, Germany, have discovered that the drug dextromethorphan, when consumed, metabolizes into a compound called dextrorphan. This compound is what triggers the insulin release from the pancreas. The drug suppresses the activity of certain receptors called N-Methyl-D-Aspartate (NMDA) in the medulla oblongata, located in the brainstem just above the spinal cord. NMDA receptors also are found in the ... Read More

Study clears Nesina of heart risk; cancer risk still questionable

The type 2 diabetes drug Nesina (alogliptin) does not increase the risk of heart failure or cardiovascular risk, according to a new study published in the journal The Lancet. Death and disability from heart disease is rampant among individuals with type 2 diabetes. Concerns have been raised over the years about how some diabetes medications affect cardiovascular health after the drug Avandia was severely restricted when studies linked the medication to fatal heart attacks. As a result, Food and Drug Administration (FDA) now requires that a comprehensive evaluation of the cardiovascular safety profile be conducted on all new diabetic therapies. ... Read More

FDA approves first wireless diabetes glucose monitoring app

The Food and Drug Administration (FDA) has approved the first seamless diabetes glucose monitoring app, which can wirelessly transmit glucose readings directly to an iPhone, giving diabetics more flexibility when it comes to managing their disease. Federal drug and medical device regulators gave a nod to the new version of the Dexcom Share platform, which works with the Dexcom G4 continuous glucose monitor (CGM). The original Dexcom Share, which was approved by the FDA in October 2014, was a docking cradle peripheral that could transmit Dexcom’s glucose readings to a nearby iPhone. The readings were then uploaded through the cloud ... Read More

Judge slaps Takeda with additional damages in Actos bladder cancer lawsuit

A Pennsylvania judge refused to overturn a $2 million verdict against Takeda Pharmaceuticals Inc. involving claims that its type 2 diabetes drug Actos caused bladder cancer, and slapped the drug company with nearly $100,000 in additional damages for the delay. Plaintiff Frances Wisniewski filed the lawsuit in Philadelphia Court of Common Pleas in July 2012 claiming she developed bladder cancer after taking Actos for seven years. In August 2011, the Food and Drug Administration (FDA) ordered Takeda to update the safety label of Actos to include warnings for bladder cancer risk in patients who used the drug for more than a ... Read More

Another Actos bladder cancer case goes to trial

In 2011, three years after John Kristufek began taking the type 2 diabetes drug Actos,, he developed bladder cancer. Coincidentally that same year, studies linked Actos to an increased risk of type 2 diabetes. Since then, evidence began to surface that Actos maker Takeda Pharmaceuticals knew its blockbuster diabetes drug could cause bladder cancer but failed to warn doctors or patients. Now, after several procedures to have recurring tumors removed and, subsequently his entire bladder removed, Kristufek is getting his day in court. Kristufek’s filed his lawsuit alleging the Actos bladder cancer link in July 2012 in the Philadelphia Court ... Read More

Most diabetics stop taking glucose-lowering medications after cancer diagnosis

Most diabetics stop taking their glucose-lowering medications after they are diagnosed with cancer, according to a study published in the journal Diabetologia. The study, conducted by researchers with the Netherlands Comprehensive Cancer Organization in Eindhoven, involved new users of type 2 diabetes drugs between 1998 and 2011 from the Eindhoven Cancer Registry-PHARMO Database Network. From that database, researchers examined 3,281 patients diagnosed with cancer and 12,891 who were not diagnosed with cancer during follow-up. A medication possession ratio was used to determine drug adherence in both groups of patients. Researchers took note not only of cancer diagnosis, but also of ... Read More

Diabetes drug Januvia linked to heart failure hospitalizations

An observational study published in the journal JACC Heart Failure raises alarming questions about the type 2 diabetes drug Januvia (sitagliptin) and heart failure. The study involved an analysis of insurance claims from a database of more than 7,600 patients with diabetes and heart failure. Researchers found that people who took Januvia were just as likely as people who did not use Januvia to die or be hospitalized for any reason. However, patients using the drug were more likely to be hospitalized for heart failure. Researchers say the results could impact whether Januvia is prescribed as an add-on therapy for ... Read More

Many newer diabetes drugs carry cancer risks

Within the past two decades, thanks in large part to diabetes experts lowering the blood sugar threshold, millions more Americans were labeled as diabetic and became eligible for medication to help regulate blood sugar levels. As a result, the diabetes drug industry boomed. Sales of diabetes drugs topped $23 billion, more than the revenues generated from the National Football League, Major League Baseball, and the National Basketball Association combined. But in the past decade, a Milwaukee Journal Sentinel and MedPage Today investigation discovered that none of the 30 new diabetes drugs were proven to improve diabetics’ risk for associated health ... Read More

Dying man warns others of Actos bladder cancer risks

Before Tom Harbert died, he wanted to warn others not to let suspicious symptoms go unchecked. By the time he doctors found the source of his painful abdominal cramps, the cancerous tumor in his bladder had already made its way through the bladder wall. Doctors told him the prognosis was grim. About 70,000 people in the United States are diagnosed with bladder cancer each year and about 15,600 die from the disease annually. The No. 1 risk factor for bladder cancer is smoking. But Harbert, 51, was not a smoker nor was he around any chemicals that would have increased ... Read More